The day was established to raise awareness about Alzheimer’s disease and its impact on the African American community, since their risk of developing Alzheimer’s disease is two to three times higher than white Americans.
A published study focused on polyamines, molecules produced by our own cells and found in the foods we eat. Polyamine supplementation could boost mitochondrial function and memory as we age.
UK Neuroscience Professor Greg Gerhardt's new research program will provide answers to questions about the role of neurotransmitters in the progression of Alzheimer’s disease.
Their work shows that direct measures of brain signatures during mental activity are more sensitive and accurate predictors of memory decline than current standard behavioral testing.
Newly published research has found familiar music can elicit an extended emotional response in patients with Alzheimer’s-type dementia. The findings from this potential new approach were featured in the Journal of Alzheimer’s Disease.
Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.
Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.
In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.
Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.
Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.
